No treatments for HD are currently available, but this disease may be a good candidate for cell replacement therapy because it is characterized by the relatively focal loss of MSNs that is caused by a mutation of HTT (Rosser and Bachoud-Lévi, 2012). This evidence concerns the gene HTT and Huntington disease.